Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition of hydroxysafflor yellow A and salvianolic acid A, and kit

A technology of hydroxy safflower and composition, applied in the directions of drug combination, cardiovascular system diseases, etc., can solve the problems of impurity exclusion, allergic reaction, complex preparation components, etc., and achieves the effect of eliminating impurities, increasing the content, and eliminating allergic reactions.

Inactive Publication Date: 2015-07-15
ZHEJIANG YONGNING PHARMA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinical application has proved its effectiveness, but the main adverse reaction of Danhong Injection is allergic reaction, which is mainly due to the complex composition of the preparation and the inability of domestic pharmaceutical technology to completely eliminate the impurities in Danhong Injection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of hydroxysafflor yellow A and salvianolic acid A, and kit
  • Pharmaceutical composition of hydroxysafflor yellow A and salvianolic acid A, and kit
  • Pharmaceutical composition of hydroxysafflor yellow A and salvianolic acid A, and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0031] 1. Test drug

[0032] Hydroxysafflower yellow A: This product is yellow powder, provided by Zhejiang Yongning Pharmaceutical Co., Ltd.

[0033] Salvianolic acid A: This product is light yellow powder, provided by Zhejiang Yongning Pharmaceutical Co., Ltd.

[0034] 2. Dose setting and grouping

[0035] 2.1. Single drug dose setting:

[0036] There are four doses of hydroxysafflower yellow A: 5mg / kg, 10mg / kg, 20mg / kg and 40mg / kg.

[0037] There are four doses of salvianolic acid A: 1.25mg / kg, 2.5mg / kg, 5mg / kg and 10mg / kg.

[0038] A normal saline control group was also set up.

[0039] 2.2. Compound ratio dose setting

[0040] Hydroxysafflower yellow A and salvianolic acid A are arranged according to the Latin square, and there are 16 groups in total. There are 4 doses of each single drug combined with the solvent control group, a total of 25 groups (see Table 1), n=10 in each group.

[0041] Table 1 The ratio between different doses of hydroxysafflower yellow A and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, specifically to a pharmaceutical composition of hydroxysafflor yellow A and salvianolic acid A, and a kit. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases comprises hydroxysafflor yellow A and salvianolic acid A. According to the invention, a compound preparation prepared from the hydroxysafflor yellow A and salvianolic acid A monomer or combined appilication of the hydroxysafflor yellow A and salvianolic acid A monomer enables the content of effective components to be effectively increased and impurities in commercially available products to be eliminated, so the current situation that the commercially available products obviously incur anaphylactic reaction is greatly improved. The pharmaceutical composition provided by the invention has substantial curative effect and is applicable to clinical application.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, in particular to a pharmaceutical composition and kit of hydroxysafflower yellow A and salvianolic acid A. Background technique [0002] The traditional Chinese medicine safflower comes from the dried flower of Carthamus tinctorious L., a plant of Compositae. Modern pharmacological studies have shown that the main active components of safflower are concentrated in water-soluble safflower yellow pigment. Safflower yellow is a flavonoid compound, which has the effects of expanding coronary arteries, anti-oxidation, and anti-inflammation. At the same time, it is also a platelet activating factor inhibitor, which can inhibit the formation of thrombus, and is used for the treatment of cardiovascular and cerebrovascular diseases. Further studies have shown that safflower yellow is a mixture of three water-soluble components: hydroxysafflor yellow-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/351A61P9/10A61P9/00A61K31/216
Inventor 叶天健阚士东陆修伟张志杰郭瑞锋
Owner ZHEJIANG YONGNING PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products